NFE2L2 and chronic myelogenous leukemia, BCR-ABL1 positive: It has been shown that treatment of the K562/A02 CML cell line by the Nrf2 inhibitor, Wogonin, is associated with a blockade of the Stat3/NF-κB signaling pathway and a reduction of Adriamycin resistance.